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Background: Ovarian cancer is a cancerous growth arising from the ovary.
Objective: This study was aimed to explore the molecular mechanism of the development and progression of the
ovarian cancer.
Methods: We first identified the differentially expressed genes (DEGs) between the ovarian cancer samples and the
healthy controls by analyzing the GSE14407 affymetrix microarray data, and then the functional enrichments of the
DEGs were investigated. Furthermore, we constructed the protein-protein interaction network of the DEGs using
the STRING online tools to find the genes which might play important roles in the progression of ovarian cancer.
In addition, we performed the enrichment analysis to the PPI network.
Results: Our study screened 659 DEGs, including 77 up- and 582 down-regulated genes. These DEGs were enriched
in pathways such as Cell cycle, p53 signaling pathway, Pathways in cancer and Drug metabolism. CCNE1, CCNB2
and CYP3A5 were the significant genes identified from these pathways. Protein-protein interaction (PPI) network
was constructed and network Module A was found closely associated with ovarian cancer. Hub nodes such as
VEGFA, CALM1, BIRC5 and POLD1 were found in the PPI network. Module A was related to biological processes
such as mitotic cell cycle, cell cycle, nuclear division, and pathways namely Cell cycle, Oocyte meiosis and p53
signaling pathway.
Conclusions: It indicated that ovarian cancer was closely associated to the dysregulation of p53 signaling pathway,
drug metabolism, tyrosine metabolism and cell cycle. Besides, we also predicted genes such as CCNE1, CCNB2,
CYP3A5 and VEGFA might be target genes for diagnosing the ovarian cancer.
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Ovarian cancer which caused an estimated 22,430 new
cases and 15,280 deaths in 2007 in the United States [1], is
the leading cause of death from gynecologic malignancy
[2]. Approximately 90% of primary malignant ovarian tu-
mors are epithelial (carcinomas), which are from the ovar-
ian surface epithelium (OSE) [3,4]. And ovarian epithelial
tumors currently contains four major types of epithelial
tumors (serous, endometrioid, clear cell, and mucinous)
based entirely on tumor cell morphology. It is well known* Correspondence: flina0413@163.com
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stated.that the symptoms of it include bloating, pelvic pain, diffi-
culty eating, frequent urination and so on. But it is diffi-
cult to diagnose ovarian cancer at its early stages (I/II) as
its most symptoms are non-specific [5].
It is all known that tumors develop and progress are
related to accumulated molecular genetic or genomic
changes such as point mutation, gene amplification, de-
letion, and translocation [6]. For instance, TP53 is mu-
tated in 50% or more high-grade serous carcinomas [7].
Besides, it have been indicated that some tumor sup-
pressor genes and oncogenes such as BRCA1/2, PTEN,
and PIK3CA also mutated and accumulated in ovarian
serous carcinomas [7-9]. Studies also demonstrated thatl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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with low-grade ovarian carcinomas, which is consistent
with the view that cyclin D1 is a downstream target
of active MAPK (mitogen-activated protein kinase)
constitutively expressed in most low-grade ovarian tu-
mors as a results of frequent activating mutations in KRAS
(v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog)
and BRAF (v-raf murine sarcoma viral oncogene homo-
log B1) [10-12]. In spite of the expanded efforts to study
the genetic bases of ovarian cancer, the molecular mecha-
nisms of the development and progression were still not
clear.
In this study, we identified the differentially expressed
genes (DEGs) between the ovarian cancer samples and
the healthy controls. In addition, we used the DAVID (The
Database for Annotation, Visualization and Integrated
Discovery) to identify the significant KEGG pathways.
Furthermore, we constructed protein-protein interaction
networks to study and identify the target genes for diag-
nosing the ovarian cancer.
Materials and methods
Data source
The gene expression profiles of GSE14407 which was con-
tributed by Bowen, N.J., et al. [13] were obtained from
National Center of Biotechnology Information (NCBI)
Gene Expression Omnibus (GEO) database (http://www.
ncbi.nlm.nih.gov/geo/). The platform of the GPL570 ([HG-
U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0
Array) was applied in the expression array. The datasets
available in this analysis contained 24 samples, including
12 ovarian cancer samples and 12 controls. These data
(CEL form) and annotation files were downloaded for fur-
ther analysis.
Identification of DEGs
After obtaining the raw data, the RMA (Robust Multi-
array Average) method [14] of the R software [15]
was used to perform quartile data normalization, then
the t test methods of the Limma package [16] was
used to identify DEGs. Values of |log Fold Change
(FC)| > 2.0 and p-value < 0.05 were selected as the cut-off
criteria.
The functional enrichment analysis of the DEGs
KEGG pathway database is a recognized and compre-
hensive database including all kinds of biochemistry
pathways [17]. In this work, the KEGG database was ap-
plied to investigate the enrichment analysis of the DEGs
to find the biochemistry pathways which might be in-
volved in the occurrence and development of ovarian
cancer. DAVID [18] was used to perform the KEGG
pathway enrichment analysis with the p-value < 0.05 and
gene count > 2.Protein-protein interaction network construction
Since proteins seldom perform their functions in isola-
tion, it is important to understand the interaction of
these proteins by studying larger functional groups of
proteins [19]. In this study, the STRING online tools
[20] were used to analyze the PPIs of the DEGs with the
cut-off criterion of combined score > 0.4. The relation-
ships of the nodes degree ≤ 5 were abandoned, then the
Cytoscape software was used to construct the network
[21]. Form the previous study, most obtained PPI net-
works obeyed the scale-free attribution [22]. So the
node degree of the network was analyzed and used to
obtain the hub protein in the PPI network. The node
degree ≥30 were selected as the threshold.
Network module analysis of the ovary cancer
The nodes and edges of the PPI network were so com-
plicate that we need to conduct the enrichment analysis
using the ClusterONE Cytoscape plug-in [23]. Minimum
size >5 and minimum density < 0.05 were the parameters
before running the ClusterONE to disclose the enriched
functional modules of the PPI network. We also per-
formed the GO (gene ontology) functional enrichment
analysis of the module genes to analyze the gene function
in the molecule level. Furthermore, the best enriched
module was performed KEGG pathway enrichment ana-
lysis using DAVID [18].Results
Identification of DEGs
Limma package in R was used to identify the DEGs be-
tween the ovarian cancer samples and the healthy con-
trols. According to the cut-off criteria of |logFC| > 2.0 and
p-value < 0.05, we finally gained 659 DEGs, including 77
up- and 582 down-regulated genes.KEGG pathways analysis
To gain further insights into the function of DEGs, DA-
VID were applied to identify the significant dysregulated
KEGG pathways. The pathways obtained with p-value <
0.05 and gene count > 2 of the up- and down-regulated
genes were showed in Table 1, respectively. According to
the enrichment results, the up-regulated genes were sig-
nificantly enriched in pathways such as Cell cycle and
p53 signaling pathway; genes including CCNE1 (cyclin E1)
and CCNB2 (cyclin B2) were identified in p53 signal-
ing pathway. Besides, the down-regulated DEGs were
enriched in Drug metabolism, Pathways in cancer and
Tyrosine metabolism significantly. CYP3A5 (cytochrome
P450, family 3, subfamily A, polypeptide 5), GSTM3
(glutathione S-transferase mu 3), MAOA (monoamine
oxidase A) were the significant genes filtered out from the
Drug metabolism pathway.
Table 1 The KEGG pathway of the DEGs
Category KEGG pathway term Count Genes P-value
Up-regulated DEGs hsa00982 drug metabolism 8 CYP3A5, GSTM3, MAOA,… 0.004592
hsa05200 pathways in cancer 21 WNT5A, BMP2, FGF9,… 0.006931
hsa00980 metabolism of xenobiotics by cytochrome P450 7 AKR1C2, CYP3A5, GSTM3,… 0.015153
hsa00350 tyrosine metabolism 6 MAOA, ALDH1A3, AOX1,… 0.015606
hsa04610 complement and coagulation cascades 7 THBD, C3, CFH, TFPI, … 0.028328
hsa00330 arginine and proline metabolism 6 GATM, MAOA, GLS, MAOB,… 0.032382
hsa04510 focal adhesion 13 CAV2, CAV1, COL3A1, MET, … 0.038664
Down-regulated DEGs hsa04110 cell cycle 7 CCNE1, CDKN2A, CCNB2,… BUB1B, 1.06E-05
hsa04115 p53 signaling pathway 5 CCNE1, CDKN2A, CCNB2,… 1.78E-04
hsa05200 pathways in cancer 7 CCNE1, FGF18, CDKN2A, … 0.002121
hsa04114 oocyte meiosis 4 CCNE1, CCNB2, AURKA,… 0.011244
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The STRING tool was used to get the PPI relationships of
the DEGs. A total of 1241 PPI relationships were gained
with the combined score > 0.4. After the nodes of degree ≤
5 were filtered out, we finally built the network with 405
nodes and 1224 edges (Figure 1). The connectivity degree
of each node of the PPI network was calculated and the
results of some nodes were shown in the Table 2. The
genes VEGFA (vascular endothelial growth factor A),
CALM1 (calmodulin 1), BIRC5 (baculoviral IAP repeat
containing 5), POLD1 (polymerase-DNA directed, delta 1,
catalytic subunit), AURKA (aurora kinase A), CDT1 (chro-
matin licensing and DNA replication factor 1), BUB1B
(BUB1 mitotic checkpoint serine/threonine kinase B) with
high connectivity degree > 30 were selected as the hub
nodes and might play important roles in the progression
of ovarian cancer.
Module analysis
PPI network enrichment was one of the main methods
to study and identify the functional proteins. In this
study, there were 9 significant modules (p value <1 × 10-3)
enriched by ClusterONE plug-in with the parameters of
minimum size > 5 and minimum density < 0.05. And the
most significant enrichments Module A (p = 1.000 × 10-4),
Module B (p = 1.350 × 10-7) and Module C (p = 5.552 ×
10-7) were showed in Figure 2. According to the Figure 2,
it was obviously that Module A might be the best module
as it has 30 nodes and 347 edges compared to Module B
with 41 nodes and 69 edges as well as Module C with 45
nodes and 59 edges.
To further study the function changes in the course of
tumor progression, we performed the GO functional
annotation of genes in the Module A, Module B and
Module C (Table 3). The GO enrichment scores of
Module A, B and C were 17.28, 2.49 and 4.39, respect-
ively. Therefore, Module A might be the most suitable
module for further functional analysis. There were 30genes in the Module A (Figure 2A), which were signifi-
cantly enriched in the biological processes such as mitotic
cell cycle, cell cycle and nuclear division. Then these genes
were investigated by KEGG pathway enrichment analysis
and the outcomes were shown in Table 4. The genes
in this module were remarkable enriched in pathways
such as Cell cycle, Oocyte meiosis, p53 signaling pathway,
Pyrimidine metabolism and Purine metabolism. CCNE1
and CCNB2 were also the significant genes enriched in
cell cycle pathway.
Discussion
Ovarian cancer is the seventh leading cause of cancer-
related death in women [24]. It is difficult to detect this
disease due to asymptomatic early-stage malignancy. Thus,
most women although initially responsive, eventually de-
velop and succumb to drug-resistant metastases [25]. So
new drug targets and biomarkers that facilitate early de-
tection of ovarian cancer are essentially needed and for
further understanding the molecular pathogenesis.
In this study, we gained 659 DEGs including 77 up-
regulated DEGs and 582 down-regulated DEGs upon gene
expression profile of GSE14407. Most of these up-regulate
DEGs were enriched in pathways of Cell cycle and p53
signaling pathway, while the down-regulated DEGs were
significantly related to pathways such as Drug metabolism,
Pathways in cancer and Tyrosine metabolism. Genes in-
cluding CCNE1, CCNB2, CYP3A5, GSTM3 and MAOA
were significantly identified in these pathways.
It had indicated that p53 signaling pathway was one
of the significant pathway enriched by up-regulated
DEGs. P53 is a critical regulator of the response to DNA
damage and oncogenic stress. It is associated with the
growth, apoptosis and cell cycle arrest of cancer cells
which can induce the inhibition of proliferation in cancer
cells. Reles et al. also found that p53 alterations correlated
significantly with resistance to platinum-based chemother-
apy, early relapse, and shortened overall survival in
Figure 1 PPI network analysis of DEGs of ovarian cancer, node stand for the protein (gene), edge stand for the interaction of proteins.










The gene in the table is the symbol of the protein (gene), degree stand for the
connectivity degree of the gene.
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fore, the dysregulation of p53 function is a frequent occur-
rence in human malignancies [27]. In this study, CCNE1
and CCNB2 of p53 signaling pathway were also up-
regulated. CCNE1 encodes a protein which belongs to the
highly conserved cyclin family. It a regulatory subunit of
CDK2 and its activity is required for cell cycle G1/S transi-
tion. A previous study indicated that its over-expression
was important to growth and survival of ovarian cancer
tumors [28]. CCNB2 encodes the cyclin B2, which could
bind to transforming growth factor beta RII and thus cyc-
lin B2/cdc2 may play a key role in transforming growth
factor beta-mediated cell cycle control. And it proved that
Figure 2 The module of PPI network of ovarian cancer. The A, B, C were respectively the modules with the lowest 3 p-value.
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as a very reliable biomarker of lung adenocarcinoma
[29]. So it indicated that p53 signaling pathway played
important roles in ovarian cancer, and CCNE1 and
CCNB2 might be potential diagnostic and therapeutic
targets in ovarian cancer.
The down-regulate DEGs were significantly enriched
in pathways such as Drug metabolism, Pathways in can-
cer and Tyrosine metabolism. The cytochromes P450
(CYPs) are key enzymes in cancer formation and cancer
treatment as they regulate the metabolic activation of a
large number of precarcinogens and participate in the
inactivation and activation of anticancer drugs [30]. Inaddition, tyrosine is a non-essential amino acid that con-
jugates with corresponding tRNA forming Tyrosine-
tRNA [31]. And targeted therapy for ovarian cancer with
tyrosine kinase inhibitors (TKIs) had been in Phase I/II
and III trials [32]. In our study, CYP3A5 was down-
regulated in the drug metabolism pathway. CYP3A5 en-
codes a member of the cytochrome P450 superfamily of
enzymes which catalyze many reactions involved in drug
metabolism [33]. Meanwhile, Downie and his co-works
indicated that CYP3A5 showed a very significantly en-
hanced expression in the primary ovarian cancers com-
pared with normal ovary [34]. The result above suggested
that Drug metabolism and Tyrosine metabolism were
Table 3 The GO analysis of the three modules
Category Term Description Count P value
Module A Enrichment score: 17.28123992198
BP GO:0000278 Mitotic cell cycle 18 1.21E-20
BP GO:0007049 Cell cycle 21 6.99E-20
BP GO:0022403 Cell cycle phase 18 8.21E-20
BP GO:0022402 Cell cycle process 19 3.72E-19
BP GO:0000279 M phase 16 5.88E-18
BP GO:0000280 Nuclear division 14 6.30E-17
BP GO:0007067 Mitosis 14 6.30E-17
BP GO:0000087 M phase of mitotic cell cycle 14 7.98E-17
BP GO:0048285 Organelle fission 14 1.07E-16
BP GO:0051301 Cell division 14 3.01E-15
Module B Enrichment score: 2.48970202313
BP GO:0009611 Response to wounding 8 5.04E-04
BP GO:0050817 Coagulation 4 2.68E-03
BP GO:0007596 Blood coagulation 4 2.68E-03
BP GO:0007599 Hemostasis 4 3.16E-03
BP GO:0050878 Regulation of body fluid levels 4 6.65E-03
Module C Enrichment score: 4.39218066431
MF GO:0003700 Transcription factor activity 15 1.97E-07
MF GO:0030528 Transcription regulator activity 18 1.97E-07
MF GO:0043565 Sequence-specific DNA binding 12 6.00E-07
BP GO:0006355 Regulation of transcription, DNA-dependent 19 7.70E-07
BP GO:0051252 Regulation of RNA metabolic process 19 1.08E-06
BP GO:0045449 Regulation of transcription 20 4.71E-05
MF GO:0003677 DNA binding 18 8.11E-05
BP GO:0006357 Regulation of transcription from 10 2.16E-04
RNA polymerase II promoter
BP GO:0006350 Transcription 16 5.92E-04
Category stands for the GO function, BP stands for biological process, MF stands for molecule function, enrichment score stands for score of GO enrichment.
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expression profile of CYP3A5 may play an important
role in the formation and treatment of ovarian cancer.
In addition, we also used STRING tool to get the PPI
relationships of the DEGs and gained the network withTable 4 The KEGG pathway of the genes in the Module A
KEGG pathway term Count Genes P-value
hsa04110 cell cycle 5 CCNE1, CCNB2,
BUB1B, TTK, PTTG1
1.00E-04





3 CCNE1, CCNB2, RRM2 0.008966
hsa00240 pyrimidine
metabolism
3 RRM2, POLD1, NME7 0.017022
hsa00230 purine
metabolism
3 RRM2, POLD1, NME7 0.041398405 nodes and 1224 edges. In the network, VEGFA,
CALM1, IRC5, POLD1, AURKA, CDT1, BUB1B were
selected as hub nodes as their connectivity degrees > 30.
VEGFA encodes a glycosylated mitogen belongs to
PDGF/VEGF growth factor family, and specifically
acts on endothelial cells and has various effects, in-
cluding mediating increased vascular permeability,
inducing angiogenesis, vasculogenesis and endothe-
lial cell growth, promot-ing cell migration, and inhibi-
ting apoptosis [35]. It is a major mediator of vascular
permeability and angiogenesis [36]. Study also indicated
VEGF-gene was express in all ovarian cancer and peri-
toneal biopsies, and it induced ascites in ovarian cancer
patients due to increased peritoneal permeability
through down-regulating the tight junction protein
Claudin 5 in the peritoneal endothelium [37]. Thus,
VEGFA might be one of the target genes for diagnosing
ovarian cancer.
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network. The Module A which contained 30 genes was
proved closely associated with ovarian cancer. With the
GO analysis, the genes in the Module A were significantly
enriched in biological processes such as mitotic cell cycle,
cell cycle and nuclear division, which indicated cell cycle
of mitosis and nuclear division cycle played important
roles in ovarian cancer. From the KEGG pathway analysis
of Module C, the pathways were also remarkablely
enriched in Cell cycle, which confirmed that the mutations
in cell cycle have a difference in ovarian cancer.
However, there are some deficiencies of our study. First,
the microarray data is not generated by ourselves but from
GEO database. Second, the data downloaded from only
one platform were comparatively simplex, so the outcome
of DEGs may have a high false positive rate. Therefore,
further experimental studies should be carried out based
on a larger sample size in order to confirm our results.
Conclusion
As a result of this preliminary study, we confirmed that
the pathogenesis of ovarian cancer were closely associ-
ated to the mutations of pathways such p53 signaling
pathway, drug metabolism, tyrosine metabolism and cell
cycle. Besides, we also indicated genes such as CCNE1,
CCNB2, CYP3A5 and VEGFA might play important roles
in ovarian cancer and they were predicted target genes
for diagnosing the ovarian cancer.
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